RecruitingPhase 2NCT05540574

Trial of Zolpidem for Sleep in Children With Autism

Randomized Placebo-Controlled Crossover Trial of Zolpidem for Sleep in Children With Autism

Sponsor

Stanford University

Enrollment

26 participants

Start Date

Aug 9, 2023

Study Type

INTERVENTIONAL

Conditions

Autism Autism Spectrum Disorder

Summary

The purpose of this study is to examine the effect of zolpidem on sleep in children and adolescents with Autism Spectrum Disorder (ASD). Zolpidem is a nonbenzodiazepine GABAa receptor agonist drug that acts as a hypnotic. To accomplish this, the investigators will use a randomized double-blind placebo-controlled crossover 8-week study design to examine the effect of zolpidem on sleep physiology as assessed by polysomnography (PSG), actigraphy, circadian rhythm, and clinical measures.

Eligibility

Min Age: 8 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Zolpidem for people with autism and autism spectrum disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 8 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.